Terns Pharmaceuticals, Inc.
TERN
Classifica tra le azioni
#3573
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Prezzo delle azioni
$52.95
Ultima sincronizzazione: 2026-05-15
Capitalizzazione di mercato
$4.77B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
529.61%
Paese
US
Scambia Terns Pharmaceuticals, Inc. (TERN)
Categoria
Healthcare
Utile per Terns Pharmaceuticals, Inc. (TERN)
Utile nel Dec 2025 TTM: $-95.63M
Secondo gli ultimi rapporti finanziari di Terns Pharmaceuticals, Inc., gli utili attuali della società sono $-95.63M. Nel 2023, la società ha registrato un utile di $-89.97M, una diminuzione rispetto a agli utili del 2022, che erano di $-59.99M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Terns Pharmaceuticals, Inc. dal 2018 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $-95.63M | 7.94% |
| 2024 | $-88.59M | -1.53% |
| 2023 | $-89.97M | 49.98% |
| 2022 | $-59.99M | 20.82% |
| 2021 | $-49.65M | 70.87% |
| 2020 | $-29.06M | -57.79% |
| 2019 | $-68.84M | 280.64% |
| 2018 | $-18.09M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $5.27B | -5,616.18% |
US
|
|
| $-3.09B | 3,128.20% |
US
|
|
| $-4.02B | 4,099.90% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -2,139.87% |
NL
|
